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ABSTRACT
Introduction Orthotopic liver transplantation (OLT) has 
emerged as the mainstay of treatment for end-stage 
liver disease. In an attempt to improve the availability 
of donor allografts and reduce waiting list mortality, 
graft acceptance criteria were extended increasingly 
over the decades. The use of extended criteria donor 
(ECD) allografts is associated with a higher incidence of 
primary graft non-function and/or delayed graft function. 
As such, several strategies have been developed aiming 
at reconditioning poor quality ECD liver allografts. 
Hypothermic oxygenated machine perfusion (HOPE) has 
been successfully tested in preclinical experiments and in 
few clinical series of donation after cardiac death OLT.
Methods and analysis HOPE ECD-DBD is an investigator-
initiated, open-label, phase-II, prospective multicentre 
randomised controlled trial on the effects of HOPE on ECD 
allografts in donation after brain death (DBD) OLT. Human 
whole organ liver grafts will be submitted to 1–2 hours of 
HOPE (n=23) via the portal vein before implantation and 
are going to be compared with a control group (n=23) 
of patients transplanted after conventional cold storage. 
Primary (peak and Δ peak alanine aminotransferase 
within 7 days) and secondary (aspartate aminotransferase, 
bilirubin and international normalised ratio, postoperative 
complications, early allograft dysfunction, duration of 
hospital and intensive care unit stay, 1-year patient 
and graft survival) endpoints will be analysed within a 
12-month follow-up. Extent of ischaemia–reperfusion (I/R) 
injury will be assessed using liver tissue, perfusate, bile 
and serum samples taken during the perioperative phase 
of OLT.
Ethics and dissemination The study was approved 
by the institutional review board of the RWTH Aachen 
University, Aachen, Germany (EK 049/17). The current 
paper represent the pre-results phase. First results are 
expected in 2018.
Trial registration number NCT03124641.
InTRoduCTIon
Since Thomas Starzl's pioneering efforts 
in 1963, orthotopic liver transplantation 
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Protocol
Strengths and limitations of this study
 ► HOPE ECD-DBD is a multicentre randomised 
controlled trial investigating the specific effects of 
Hypothermic oxygenated machine perfusion (HOPE) 
on extended criteria donor (ECD) organs in donation 
after brain death (DBD) transplantation.
 ► Tissue, blood, perfusate and bile-samples, retrieved 
for translational research, will enable an in-depth 
analysis of the effects of HOPE on ischaemia–
reperfusion injury and inflammation.
 ► The stratified randomisation model will allow us 
to achieve a homogeneous distribution of patients 
between treatment groups based on prognostic 
variables.
 ► Open-label design is considered a limitation of the 
study. Owing to the nature of the surgical procedure, 
it is not possible to blind the surgical team for the 
group allocation.
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(OLT) has evolved as the standard therapy for patients 
with end-stage liver disease.1 In 2015, approximately 
1500 patients were listed for liver transplantation in 
Germany with only 894 transplants performed due to 
organ shortage.2 Several strategies for donor pool expan-
sion are being pursued concurrently. These include the 
use of living donors, splitting of cadaveric livers for two 
recipients and the use of extended criteria donor (ECD) 
allografts for OLT. These ECD allografts, however, exhibit 
poor tolerance to ischaemia–reperfusion (I/R) injury, an 
important cause of liver damage. As such, I/R injury is the 
underlying cause of graft dysfunction in ECD allografts 
and negatively affects the process of liver regeneration 
in surgical conditions including hepatic resections and 
OLT.2 
Accordingly, several strategies have been developed, 
aiming at reconditioning poor quality ECD allografts.3–7 
Hypothermic oxygenated machine perfusion (HOPE) 
has been tested intensively in preclinical animal experi-
ments.3 The positive effects of HOPE in this setting have 
been demonstrated among others to reduce the inci-
dence of biliary complications, mitochondrial damage 
and level of cellular energy status.3 In the clinical setting, 
hypothermic oxygenated organ perfusion is performed 
in the transplant centre shortly before the actual implan-
tation using an extracorporal organ perfusion system 
with full oxygen saturation over the portal vein.3 The 
first clinical study with HOPE was recently published by 
Dutkowski et al in a cohort of patients undergoing OLT 
with donation after cardiac death (DCD) allografts.8 
In donation after brain death (DBD), the only legally 
accepted approach for organ donation in Germany and 
many other European countries, HOPE and its effect on 
early graft function and postoperative complications has 
not been reported yet.2
The purpose of this study is to test the effects of 
HOPE in a prospective multicentre randomised clinical 
trial (RCT) on ECD liver allografts in DBD liver trans-
plantation compared with conventional cold storage 
(CCS; HOPE ECD-DBD). As such, we hypothesise that 
HOPE might have an organ reconditioning effect by 
substantially reducing early allograft injury in predam-
aged ECD organs. Primary (peak and Δ peak alanine 
aminotransferase (ALT) within 7 days) and secondary (eg, 
peak aspartate aminotransferase (AST), bilirubin (BR) 
and international normalised ratio (INR), lactate, post-
operative complications, hospital stay, graft and patient 
survival) endpoints are going to be analysed. I/R injury 
and biomarkers of HOPE-induced subcellular responses 
will be assessed using liver tissue, perfusate, bile and 
serum samples during the perioperative phase of OLT. 
Follow-up is set at 12 months.
METhodS And AnAlySIS
Study type
HOPE ECD-DBD is an investigator initiated, open-label, 
phase-II, prospective multicentre randomised controlled 
trial on ECD allografts in DBD OLT. Figure 1 summarises 
the trial design. The study protocol was written in accor-
dance to the Consolidated Standards of Reporting 
Trials (CONSORT) and Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) 
recommendations.
Eligibility
Patients above 18 years of age, suffering from end stage-
liver disease and/or malignant liver tumours, listed for 
OLT and receiving ECD organs at the Department of 
Surgery and Transplantation, University Hospital RWTH 
Aachen, Aachen, Germany, and at other participating 
centres, are eligible for the study. Informed consent is 
obtained from all subjects participating in the trial by 
a qualified member of the study team in the outpatient 
clinic. In each centre, potential study participants on the 
OLT waiting list will be screened for defined inclusion 
and exclusion criteria and will be enrolled accordingly 
(figure 1). Allocation of liver allografts follows national 
(German Foundation for Organ Transplantation, The 
Belgian Transplantation Society, Romanian National 
Transplant Agency) and/or European (Eurotransplant 
(ET)) policies. The study will not influence the allocation 
procedure or cause any delay in the actual implantation 
procedure.
Inclusion criteria
Inclusion criteria are
1. signed informed consent
2. patients 18 years or older
3. patients suffering from end stage-liver disease and/or 
malignant liver tumours
4.  listed for OLT
5.  receiving ECD allografts.
Exclusion criteria
Exclusion criteria are
1. recipients of split or living donor OLT
2.  previous OLT
3.  combined transplantations (liver-kidney, liver-lung, 
etc.)
4.  participation in other liver-related trials
5.  the subject received an investigational drug within 
30 days prior to inclusion
6.  the subject is unwilling or unable to follow the proce-
dures outlined in the protocol
7.  the subject is mentally or legally incapacitated
8.  an inability to understand the procedures due to lan-
guage barriers
9.  family members of the investigators or employees of 
the participating department.
Randomisation
Randomisation is performed at arrival of the allograft at 
the transplant centre and after acceptance for transplan-
tation, using an online randomising tool for clinical trials 
(www. randomizer. at), either by the principal investigator 
or, in case of absence, by a trained member of the study 
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Figure 1 Study flowchart. alphaGST, alpha gluthation S-transferase; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; BR, bilirubin; CCS, conventional cold storage; CRF, case report file; ECD, extended criteria donor; GFR, 
glomerular filtration rate; HOPE, hypothermic oxygenated machine perfusion; INR, international normalised ratio; OLT, 
orthotopic liver transplantation.
team.9 10 A stratified randomisation model will be used 
to ensure a balance of prognostic variables between the 
treatment groups. Expected cold ischaemia time and 
graft steatosis were selected for stratification. A median 
cold ischaemic time of 8 hours is based on our local OLT 
database (2010–2017) containing more than 320 OLTs. 
Therefore, 8 hours of expected cold ischaemia time has 
been selected as a cut-off value for this study. For steatosis, 
we use 30% macrovesicular steatosis as a cut-off value for 
the stratification process as defined by the NASH Clin-
ical Research Network Scoring System and validated as 
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Figure 2 Hypothermic oxygenated machine perfusion (HOPE). First the donor organ is retrieved and transported to the 
transplant centre in a conventional way. In the transplant centre, the liver is connected to the liver assist device and HOPE 
is performed. Hypothetically, organ reconditioning with HOPE triggers multiple protective responses leading to decreased 
oxidative stress, improved energy reserves, reduced cell death. CCS, conventional cold storage; ET, Eurotransplant; ROS, 
reactive oxygen species. Adapted from Schlegel et al.24
prognostic marker in liver transplantation by several 
authors.11–14
organ procurement, ECd criteria
All ECD liver allografts will be retrieved by ET and/or 
national procurement teams. Following cross-clamping 
(in situ flushing of the abdominal organs and begin of 
cold ischaemia time), allografts will be removed and 
transported in a standardised fashion of CCS on packed 
ice (4°C–6°C). Required data of the donor and the organ 
will be registered in a standard manner and will be trans-
ferred to a designated case report file (CRF).
Definition of ECD based on the recommendations of 
the German Medical Chamber (Bundesaerztekammer): 15
1.  donors 65 years of age and older
2.  intensive care therapy of the donor was required be-
fore donation for at least 7 days
3.  obesity of the donor with a body mass index >30 kg/
m²
4.  fatty liver (with histology) >40%
5.  serum sodium >165 mmol/L
6.  serum AST or ALT >3 times the upper limits of nor-
mal
7.  serum BR>2 mg/dL.
hoPE versus CCS
The present RCT comprises two groups, a perfusion 
(group 1; HOPE) and a control CCS (group 2) group. 
Patients on the waiting list for OLT with proven written 
consent will be recruited.
In case of randomisation to group 1, HOPE will be 
applied to the allograft in the operating room after 
regular organ procurement, transport and back-table 
preparation (figure 2) according to a protocol previously 
described by Dutkowski et al for DCD liver transplanta-
tion.8 HOPE (Liver Assist; Organ Assist b.v., Groningen, 
The Netherlands) will be applied through the portal vein 
for 1–(2) hour(s) (if recipient hepatectomy is prolonged, 
HOPE will be continued to avoid repeated static cold 
storage), with a perfusion rate of 0.1 mL/g liver/min in 
a pressured control system with 2–3 mm Hg. The 10°C 
perfusate (3–4 L) will be re-circulated (Belzer MPS, 
Bridge to Life, London, UK). Perfusate will be oxygen-
ised with a pO2 of 60–80 kPa by an oxygenator included as 
disposable in the setup. Perfusion parameters registered 
by the device will be stored automatically and evaluated 
for possible patterns. Immediately prior to perfusion, 
grafts are flushed with machine perfusion solution to 
wash out the residual HTK perfusate. Storage, manage-
ment and use of the above-mentioned medical products 
will be carried out according to the manufacturer’s guide-
lines. Patients in the CCS control group will undergo the 
clinically routine procedure with CCS using HTK solu-
tion (Custodiol, Dr Franz Köhler Chemie, Bensheim, 
Germany) according to institutional protocols.
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Figure 3 Interventions and study visits. Arabic numbers represent the single study visits. Visit 1: screening, enrolment; visit 
2: admission; visits 3, 4, 5: postoperative days 1, 2, 3; visit 6: seventh postoperative day; visit 7: discharge; visit 8: 6 months 
follow-up; visit 9: 12 months follow-up, final visit HOPE, hypothermic oxygenated machine perfusion.
orthotopic liver transplantation
In centre 1, OLT will be performed using the total cava 
replacement technique with veno-venous bypass including 
the portomesenteric vascular bed using a roller pump 
system with an adjustable flow as previously described.16 17 
Biliary reconstruction will be performed as a side-to-side 
common bile duct anastomosis with T-tube insertion 
or primary Roux-en-Y hepaticojejunostomy in cases of 
primary sclerosing cholangitis as previously described.18 
External centres will use their local standard techniques 
for OLT.
Sample collection and storage
I/R injury will be assessed using liver tissue samples taken 
on arrival of the organ (before HOPE or CCS) and at the 
end of implantation before closure of the abdomen, to 
evaluate the amount of I/R injury (figure 3). In total, 
two excision biopsies (2 cm3) will be harvested from the 
ECD liver allograft (segment III). Perfusate samples will 
be collected repeatedly during machine perfusion. Blood 
samples are taken as part of the daily routine during the 
perioperative and postoperative course of OLT (figure 3). 
Blood parameters of liver tissue damage and/or function 
(serum AST, ALT, BR, albumin, INR, alpha-gluthation 
S-transferase (GST), lactate) as well as kidney damage 
and/or function (creatinine, urea, glomerular filtration 
rate using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation) will be monitored. An 
additional 20 mL blood will be drawn on hospital admis-
sion and on postoperative days 1, 2, 3 and 7 (POD 1, POD 
2, POD 3 and POD 7) and will be used for translational 
research (figure 3). Bile samples can be easily collected 
from the T-Drain during the first three PODs (only appli-
cable for centre 1). All liver tissue, serum, perfusate, and 
bile samples will be directly snap-frozen in liquid nitrogen 
(−80°C) and stored for 12 months after completion of the 
trial.
Postoperative care and immunosuppression
All patients are treated in accordance to our institution's 
routine clinical algorithm for OLT recipients. Apart for 
the ex vivo allograft perfusion (group 1, HOPE), patients 
will be treated according to standard operating proce-
dures for perioperative medical, interventional and 
surgical OLT management. Patients after OLT will be 
monitored at the intensive care unit (ICU) during the 
early postoperative phase and later, depending on their 
individual recovery, transferred to regular ward.
The used immunosuppressive regimen is based on 
induction therapy with intravenous basiliximab and 
methylprednisolone followed by corresponding oral 
doses of prednisolone, tacrolimus and mycophenolate 
mofetil.16 17
Study endpoints
Primary endpoints
Early graft injury in DBD-OLT using ECD allografts under-
going HOPE or CCS, as assessed by peak ALT during the 
first 7 days post-OLT and by Δ peak ALT*.19
Secondary endpoints
1. Incidence of postoperative complications as assessed 
by the Clavien-Dindo complication score and the 
comprehensive complication index.20
2. Further laboratory parameters such as serum AST, 
BR, INR, platelet count, albumin, creatinine, urea, 
lactate, glomerular filtration rate using the CKD-EPI 
equation, alpha-GST.
3. Early allograft dysfunction as defined by the Olthoff 
criteria (BR≥10 mg/dL on day 7, INR≥1.6 on day 7 
and ALT or AST>2000 IU/L within the first 7 days).21
4. Duration of intensive care stay.
5. Duration of hospital stay.
6. One-year recipient and graft survival.
7. Analysis of serum, tissue, bile and perfusate biomarkers 
as translational aspects of the project.
*Δ Peak ALT: To correct for an assumed washout effect 
of machine perfusion, besides the absolute values, relative 
changes of serum peak ALT will be assessed.19 Peak ALT 
will be corrected to the values measured in the routine 
blood analysis after reperfusion at the time point of 
admission to the ICU.
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Power of the study
A sample size of 23 patients per group (Σn=46) was calcu-
lated with the G*Power software (Heinrich-Heine-Univer-
sity, Düsseldorf, Germany) using the following settings: 
α=0.05; 1-β(power)=0.8; two-sided t-test, including 15% 
drop-out and invalid data; peak AST and ALT levels 
48 hours post-transplantation. Power calculation was 
performed based on the previous data from Guarrera et 
al.22 A reduction of 65% (AST)–59% (ALT) is expected 
in the mean peak transaminase levels following machine 
perfusion treatment (peak AST: MP, 1154±355.5 SD IU/
mL, CCS, 3339±3376.90.1 SD IU/mL; peak ALT: MP, 
560.0±355.5 SD IU/mL, CCS, 1358±1208.4 SD IU/mL).22
data collection and statistics
All collected data are documented on CRFs and consid-
ered as source data. Members of the study team docu-
ment the required information into the CRF system 
following previous training. A study database will be 
created based on the CRFs and data correction, record 
keeping, archiving and subsequently the destruction of 
study documents will be performed according to the 
international conference on harmonisation-good clin-
ical practice (ICH-GCP) guidelines. Subjects will be 
informed about data protection and that data will be 
pseudonymised. Furthermore, data will be handed out to 
third party only anonymised. Encoded data will only be 
provided to authorised persons (clinical monitor, autho-
rised study staff, authorities, institutional review board). 
The study will be prematurely terminated for an indi-
vidual subject in case of study-related complications or if 
the subject withdraws informed consent. Values of p value 
less than 0.05 will be considered significant. Unpaired 
t-test and Mann-Whitney U test are going to be applied 
in case of normally and non-normally distributed data, 
respectively. For time course analysis of laboratory param-
eters, two-way analysis of variance is applied. Postopera-
tive complications are assessed by the Fischer’s exact test. 
For comparisons between Kaplan-Meier curves of 1-year 
graft and patient survival, the log-rank test is used.
Analysis of primary endpoints will be performed by an 
independent committee in a blinded fashion (Institute 
for Medical Statistics, RWTH Aachen).
Safety considerations
In this study, solely certified medical products (CE certifi-
cation) will be used. Blood draws and liver biopsies during 
the transplant procedure are performed according to 
the clinical routine. Thus, no relevant study-related risks 
and no additional burden for the subjects are expected. 
Independent monitoring of data will be performed 
by the Clinical Trial Center Aachen (RWTH Aachen, 
Aachen, Germany). An interim analysis will be performed 
as soon as 12 patients are enrolled in each randomised 
group. The trial will be terminated immediately if one 
of the following criteria is fulfilled: significantly higher 
serum ALT levels (p<0.001 using Student's t-test) in the 
HOPE group compared with the CCS group (efficacy). 
The proportion of grade≥III complications is significantly 
higher (p<0.05, Fischer's exact test) in the HOPE group 
when compared with the CCS group (safety).
Ethics
This study will be conducted in compliance with the 
protocol, the current version of the Declaration of Helsinki, 
and good clinical practice guidelines (ICH-GCP) as well as 
all national legal and regulatory requirements. The insti-
tutional review board of the University RWTH Aachen 
has approved the study protocol, including consent form 
and patient information (EK 049/17). Members of the 
local study team have completed a course in good clinical 
practice as certified by the German Medical Chamber. 
The trial was registered on  clinicaltrial. gov on 20.03.2017 
(NCT03124641).
Study group
The study group of the HOPE ECD-DBD trial comprises 
the trial sponsor (GL, UPN, ZC) and the PI (GL) of the 
University Hospital RWTH Aachen (centre 1), the local 
investigators in Ghent (centre 2; XR), Bucharest (centre 
3; IP, FB) and Prague (centre 4; JF). Each local investigator 
is in charge of the execution of the study and collection of 
data. The trial sponsor is responsible for randomisation, 
trial database, storage, statistical analysis and scientific 
writing. The trial will expectedly include the first patients 
(applicable for centre 1) in Q3 of 2017. External centres 
are expected to start the recruitment phase until the end 
of 2017.
I/R injury and inflammation
I/R injury, depleted energy reserves and oxidative stress 
play an important role in early graft dysfunction following 
liver transplantation of ECD liver grafts.3 4 8 23–26 The trans-
lational research aim of this study is to determine the 
effects of HOPE on I/R injury, inflammation and energy 
household on human liver ECD allografts. Blood and liver 
tissue samples will be used to measure various parameters 
of inflammation (interleukins, tumour necrosis factor-
alpha, macrophage migration inhibitory factor),27 28 
hepatocyte cell death (eg, circulating cytokeratin 18 frag-
ments like M30 or M65),29 energy (ATP levels)30 and 
redox household (hemoxygenase-1, malondialdehyde).28 
Luminometry, spectrophotometry, Luminex® assay, 
ELISA, Real-Time-PCR and western blot will be used for 
these analyses. Proteomics and metobolomics analysis will 
be performed on paired liver tissue samples to poten-
tially identify early mediators of HOPE-mediated organ 
protection.
Biochemical parameters of biliary epithelial cell func-
tion and injury (BR, biliary pH, bicarbonate, biliary 
glucose, lactate dehydrogenase, alkaline phosphatase, 
gamma-glutamyltransferase) will be assessed using stan-
dard laboratory methods.19 31
Due to the scarcity of clinical data regarding the utili-
sation of HOPE for quality assessment of liver grafts, it is 
still unclear whether this method is applicable for such 
 o
n
 25 M
arch 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-017558 on 10 October 2017. Downloaded from 
 7Czigany Z, et al. BMJ Open 2017;7:e017558. doi:10.1136/bmjopen-2017-017558
Open Access
Table 1 Active RCTs on HOPE in OLT on clinicaltrials.gov (search date: 26 August 2017)
Trial number Study centre Study type Enrolment Donor group Primary endpoint Comment
NCT03124641 
(present trial)
RWTH Aachen 
University, Aachen, 
Germany
RCT 46 ECD-DBD Early graft function 
(peak ALT level)
Recruiting
NCT01317342 University of Zurich, 
Zurich, Switzerland
RCT 170* DBD
(ECD subgroup 
analysis only)
Major postoperative 
complications (Clavien 
grade≥III) and CCI*
Recruiting
NCT02584283 University of 
Groningen, 
Groningen, 
Netherlands
RCT 156 DCD
(Maastricht 
category III)
Incidence of 
symptomatic NAS
Recruiting
*Information based on personal communication.
ALT, alanine aminotransferase; CCI, comprehensive complication index; DBD, donation of the brain death; DCD, donation of the cardiac 
death; ECD, extended criteria donation; HOPE, hypothermic oxygenated machine perfusion; NAS, non-anastomotic biliary strictures; OLT, 
orthotopic liver transplantation; RCT, randomised controlled trial; RWTH, Rheinisch-Westfälische Technische Hochschule.
quality predictions. Therefore, we will use the perfusion 
fluid to assess certain parameters which might have a 
predictive value in evaluating graft quality under hypo-
thermic conditions (pH, lactate, PO2, PCO2, AST, ALT, 
LDH, GST liver fatty acid binding protein levels).31–33
dISCuSSIon
Liver transplantation is the treatment of choice for 
patients with end-stage liver disease. The need to obtain 
the optimal benefit from a limited number of organs that 
are available has prompted the expansion of allograft 
selection criteria (ECD allografts) aiming at increasing 
the donor pool and decrease overall waiting list mortality. 
ECD allografts exhibit poor tolerance to I/R injury, a 
syndrome initiated on restoration of blood supply after 
cold and warm ischaemia yielding in endothelial and 
Kupffer cell activation, vasoconstriction, neutrophil infil-
tration and sinusoidal platelet aggregation.34 35
Technical innovations have been introduced to over-
come these difficulties of ECD allograft usage in OLT.4 
The implementation of machine perfusion for liver 
allografts was one of the most promising innovations 
in organ preservation over the last decade.4 In vivo and 
ex vivo machine perfusion of liver allografts has been 
tested intensively in preclinical studies,3 and the bene-
ficial effects of HOPE have been demonstrated among 
others to reduce the incidence of biliary complications, 
the degree of mitochondrial damage and the level of 
cellular energy status.3 In a recent international-matched 
case analysis, Dutkowski et al demonstrated for the first 
time that HOPE treatment of DCD allografts significantly 
decreased graft injury compared with matched CCS livers 
regarding peak ALT levels (1239 vs 2065 U/L, p=0.02), 
intrahepatic cholangiopathy (0% vs 22%, p=0.015) and 
overall biliary complications (20% vs 46%, p=0.042), thus 
concluding that HOPE seems to offer beneficial effects 
in DCD allograft preservation.8 In DBD, the only legally 
accepted approach for organ donation in Germany 
and many other countries, HOPE and its effect on graft 
function and postoperative complications has not been 
reported yet.2 Currently, we identified four active clinical 
trials on  clinicaltrials. gov using HOPE in liver transplanta-
tion. Two trials are non-randomised observational studies 
both with the enrolment of 10 patients for machine perfu-
sion, using different perfusion systems (NCT03098043; 
NCT03031067). One trial (NCT02584283) is a multi-
centre RCT investigating the effects of portal and arte-
rial perfusion HOPE (dual-HOPE) versus cold storage on 
biliary complications in DCD transplantation (table 1). 
Preliminary data with dual-HOPE have been reported 
recently in a case–control feasibility and safety study by 
the same group.36 The second RCT by Dutkowski et al 
(NCT01317342) is recruiting patients in DBD transplan-
tation, however, also including non-ECD organs thus 
appearing less suitable to investigate the specific effects 
of HOPE in ECD allografts (table 1).
HOPE using single (portal vein only) or dual 
(portal vein and hepatic artery) perfusion is subject 
of ongoing debate.24 36–40 Arguments for the use of 
dual perfusion are based predominantly on the better 
perfusion and preservation of the biliary system and 
reduced incidence of biliary complications in DCD 
transplantation.36 39 However, according to some 
experimental data a complete end effective perfusion 
of the graft and the biliary system can also be achieved 
by using portal vein only perfusion.38 Due to the lack 
of any in vivo clinical evidence or convincing compar-
ative preclinical data which would demonstrate the 
superiority of any of the two approaches, we decided 
to use the pragmatic approach and perfuse the liver 
grafts via the portal vein only. The favourable effects 
of portal vein only HOPE have already been success-
fully demonstrated in clinical liver transplantation 
by Dutkowski et al.8 Nevertheless, the comparison of 
single versus dual HOPE is of upmost clinical impor-
tance and should be addressed in future trials.
Although we have designed our trial carefully, 
non-blinding of the transplant team for the treatment 
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groups is a limitation. This may be accounted to the 
nature of the surgical procedure and to pragmatic 
reasons, as HOPE and back-table preparation of the 
allograft are usually performed in the same operating 
room as the OLT procedure itself. The present trial has 
also some specific strengths. First, HOPE ECD-DBD 
focuses on patients solely receiving ECD allografts, a 
population we anticipate the best cost–benefit ratio 
from the utilisation of HOPE. Second, DBD is the most 
frequent source of ECD allografts in Europe. Third, 
we use a stratified randomisation model that allows 
us to achieve a homogeneous distribution based on 
prognostic variables of patients between the groups. 
Lastly, the results of the translational part of this study 
may deliver novel insights on the underlying subcel-
lular effects of HOPE in human allografts.
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